Synthaverse Dividendo
Dividendo criteri di controllo 0/6
Synthaverse does not have a record of paying a dividend.
Informazioni chiave
n/a
Rendimento del dividendo
-0.2%
Rendimento del riacquisto
| Rendimento totale per gli azionisti | -0.2% |
| Rendimento futuro dei dividendi | n/a |
| Crescita dei dividendi | n/a |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | n/a |
Aggiornamenti recenti sui dividendi
Nessun aggiornamento
Recent updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking
Apr 20
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems
Apr 18BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly
Oct 14More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%
Nov 29We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings
Nov 16Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?
May 02Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?
Mar 08What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?
Jan 29
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 03BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt
Dec 07Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Insufficient data to determine if SVE's dividends per share have been stable in the past.
Dividendo in crescita: Insufficient data to determine if SVE's dividend payments have been increasing.
Rendimento dei dividendi rispetto al mercato
| Synthaverse Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (SVE) | n/a |
| Fondo del 25% del mercato (PL) | 2.8% |
| Top 25% del mercato (PL) | 8.0% |
| Media del settore (Biotechs) | 1.5% |
| Analista previsionale (SVE) (fino a 3 anni) | n/a |
Dividendo notevole: Unable to evaluate SVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividendo elevato: Unable to evaluate SVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Distribuzione degli utili agli azionisti
Copertura degli utili: Insufficient data to calculate SVE's payout ratio to determine if its dividend payments are covered by earnings.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Unable to calculate sustainability of dividends as SVE has not reported any payouts.